Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia
-
Published:2010-08-20
Issue:24
Volume:28
Page:3890-3898
-
ISSN:0732-183X
-
Container-title:Journal of Clinical Oncology
-
language:en
-
Short-container-title:JCO
Author:
Lugthart Sanne1, Gröschel Stefan1, Beverloo H. Berna1, Kayser Sabine1, Valk Peter J.M.1, van Zelderen-Bhola Shama Lydia1, Jan Ossenkoppele Gert1, Vellenga Edo1, van den Berg-de Ruiter Eva1, Schanz Urs1, Verhoef Gregor1, Vandenberghe Peter1, Ferrant Augustin1, Köhne Claus-Henning1, Pfreundschuh Michael1, Horst Heinz A.1, Koller Elisabeth1, von Lilienfeld-Toal Marie1, Bentz Martin1, Ganser Arnold1, Schlegelberger Brigitte1, Jotterand Martine1, Krauter Jürgen1, Pabst Thomas1, Theobald Matthias1, Schlenk Richard F.1, Delwel Ruud1, Döhner Konstanze1, Löwenberg Bob1, Döhner Hartmut1
Affiliation:
1. From Erasmus University Medical Center, Rotterdam; Free University Medical Center, Amsterdam; University Medical Center Groningen, Groningen, the Netherlands; University Hospital Ulm, Ulm; Klinik für Onkologie und Hämatologie, Städtische Kliniken Oldenburg, Oldenburg; Klinik für Innere Medizin I, Universitätskliniken des Saarlandes, Homburg; Medizinische Klinik und Poliklinik III, Universitätsklinikum Schleswig-Holstein, Kiel; Medizinische Klinik und Poliklinik III, Universitätsklinikum Bonn, Bonn;...
Abstract
PurposeAcute myeloid leukemia (AML) with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) [inv(3)/t(3;3)] is recognized as a distinctive entity in the WHO classification. Risk assignment and clinical and genetic characterization of AML with chromosome 3q abnormalities other than inv(3)/t(3;3) remain largely unresolved.Patients and MethodsCytogenetics, molecular genetics, therapy response, and outcome analysis were performed in 6,515 newly diagnosed adult AML patients. Patients were treated on Dutch-Belgian Hemato-Oncology Cooperative Group/Swiss Group for Clinical Cancer Research (HOVON/SAKK; n = 3,501) and German-Austrian Acute Myeloid Leukemia Study Group (AMLSG; n = 3,014) protocols. EVI1 and MDS1/EVI1 expression was determined by real-time quantitative polymerase chain reaction.Results3q abnormalities were detected in 4.4% of AML patients (288 of 6,515). Four distinct groups were defined: A: inv(3)/t(3;3), 32%; B: balanced t(3q26), 18%; C: balanced t(3q21), 7%; and D: other 3q abnormalities, 43%. Monosomy 7 was the most common additional aberration in groups (A), 66%; (B), 31%; and (D), 37%. N-RAS mutations and dissociate EVI1 versus MDS1/EVI1 overexpression were associated with inv(3)/t(3;3). Patients with inv(3)/t(3;3) and balanced t(3q21) at diagnosis presented with higher WBC and platelet counts. In multivariable analysis, only inv(3)/t(3;3), but not t(3q26) and t(3q21), predicted reduced relapse-free survival (hazard ratio [HR], 1.99; P < .001) and overall survival (HR, 1.4; P = .006). This adverse prognostic impact of inv(3)/t(3;3) was enhanced by additional monosomy 7. Group D 3q aberrant AML also had a poor outcome related to the coexistence of complex and/or monosomal karyotypes and cryptic inv(3)/t(3;3).ConclusionVarious categories of 3q abnormalities in AML can be distinguished according to their clinical, hematologic, and genetic features. AML with inv(3)/t(3;3) represents a distinctive subgroup with unfavorable prognosis.
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Cited by
206 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|